

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Jinhai Medical Technology Limited**

**今海醫療科技股份有限公司**

*(Incorporated in the Cayman Islands with members' limited liability)*

**(Stock Code: 2225)**

### **VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE**

This is a voluntary announcement made by Jinhai Medical Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to inform the Company’s shareholders (the “**Shareholders**”) and potential investors of the latest business update of the Group.

As mentioned in the announcements of the Company dated 25 September 2023, 18 October 2023, 22 July 2024 and 27 September 2024, amongst others, the Group is actively developing its business of provision of minimally invasive surgery solution and medical products and related services in the People’s Republic of China (the “**PRC**”) and expanding the Group’s business in the medical industry. For further details, please refer to the announcements of the Company dated 25 September 2023, 18 October 2023, 22 July 2024 and 27 September 2024 respectively.

The Board would like to inform the Shareholders that Shanghai Jinhai Xiehuan Medical Technology Limited (今海協寰醫療科技有限公司) (“**Jinhai Xiehuan**”), a wholly-owned subsidiary of the Company, has recently entered into a master sales agreement with Sinopharm Holdings Lingshang Hospital Management Services (Shanghai) Co., Ltd. (國藥控股菱商醫院管理服務(上海)有限公司) (“**Sinopharm Lingshang**”), pursuant to which Jinhai Xiehuan authorized Sinopharm Lingshang to be the exclusive distributor of the Group’s certain high-ended medical devices in the PRC for a term up to October 2025.

Sinopharm Lingshang is a joint venture company jointly established by Sinopharm Group Co., Ltd. and Mitsubishi Corporation of Japan. As an integrated operation service provider of medical consumables, Sinopharm Lingshang is committed to building a digital supply chain service platform based on big data and interconnected information systems to provide customers with full supply chain solutions. Leveraging on Sinopharm Lingshang’s extensive distribution network and strong market influence, it is expected that the Group’s principal products can be presented in a wider market and achieve rapid growth. In particular, the Group’s 4K3D fluorescent endoscopes, intervertebral foraminal endoscopes and supporting instrument sets have shown strong market competitiveness and growth potential. The Company has been taking initiatives to develop the business of the Group with an objective to broaden its income stream and eventually to maximise the return to the Shareholders. It is expected that the cooperation with Sinopharm Lingshang will further consolidate and expand the market share of these products, bringing positive return to the Shareholders as a whole.

**Shareholders and potential investor of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Jinhai Medical Technology Limited**  
**Chen Guobao**  
*Chairman of the Board and executive Director*

Hong Kong, 3 January 2025

*As at the date of this announcement, the Board comprises eight Directors, of which four are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping and Mr. Dai Yong; one is non-executive Director, namely Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.*